1-2 of 2
Bing Xu
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Orelabrutinib for the treatment of relapsed or refractory MCL: a phase 1/2, open-label, multicenter, single-arm study

Clinical Trials & Observations
Li-Juan Deng, Ke-Shu Zhou, Li-Hong Liu, Ming-Zhi Zhang, Zhi-Ming Li, Chun-Yan Ji, Wei Xu, Ting Liu, Bing Xu, Xin Wang, Su-Jun Gao, Hui-Lai Zhang, Yu Hu, Yan Li, Ying Cheng, Hai-Yan Yang, Jun-Ning Cao, Zun-Min Zhu, Jian-Da Hu, Wei Zhang, Hong-Mei Jing, Kai-Yang Ding, Xiang-Yang Zhang, Ren-Bin Zhao, Bin Zhang, Ya-Min Tian, Yong-Ping Song, Yu-Qin Song, Jun Zhu
Journal: Blood Advances
Blood Adv (2023) 7 (16): 4349–4357.
https://doi.org/10.1182/bloodadvances.2022009168
Published: 2023
Includes: Supplemental data
Journal Articles

A refined cell-of-origin classifier with targeted NGS and artificial intelligence shows robust predictive value in DLBCL

Zijun Y. Xu-Monette, Hongwei Zhang, Feng Zhu, Alexandar Tzankov, Govind Bhagat, Carlo Visco, Karen Dybkaer, April Chiu, Wayne Tam, Youli Zu, Eric D. Hsi, Hua You, Jooryung Huh, Maurilio Ponzoni, Andrés J. M. Ferreri, Michael B. Møller, Benjamin M. Parsons, J. Han van Krieken, Miguel A. Piris, Jane N. Winter, Fredrick B. Hagemeister, Babak Shahbaba, Ivan De Dios, Hong Zhang, Yong Li, Bing Xu, Maher Albitar, Ken H. Young
Journal: Blood Advances
Blood Adv (2020) 4 (14): 3391–3404.
https://doi.org/10.1182/bloodadvances.2020001949
Published: 2020
Includes: Supplemental data